|
Synonyms: IBI-306 | IBI306 | Sintbilo®
tafolecimab is an approved drug (China (2023))
Compound class:
Antibody
Comment: Tafolecimab (IBI-306; Innovent Biologics) is a fully human proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody. Based on protein sequence alignments, we suspect that tafolecimab is one of the monoclonals that are claimed in Innovent Biologics' patent US11485795: Anti-PCSK9 antibody and use thereof [4].
|
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (China (2023)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 11061 | tafolecimab |
| Synonyms |
| IBI-306 | IBI306 | Sintbilo® |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 972 |
| Other databases | |
| GtoPdb PubChem SID | 479821307 |
| Search PubMed clinical trials | tafolecimab |
| Search PubMed titles | tafolecimab |
| Search PubMed titles/abstracts | tafolecimab |
